Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Mark S WilliamsNaseer J BasmaFabio M R AmaralDaniel H WisemanTim C P SomervaillePublished in: BMC cancer (2021)
We found that chemorefractory blasts from leukemias with varied genetic backgrounds expressed a common transcriptional program. In contrast to the notion that LSC quiescence confers resistance to chemotherapy we find that refractory blasts are both actively proliferating and enriched with LSC maintenance genes. Using primary patient material from a relevant clinical context we also provide further support for the role of FOXM1 in chemotherapy resistance, proliferation and stem cell function in AML.
Keyphrases
- acute myeloid leukemia
- induced apoptosis
- genome wide
- locally advanced
- allogeneic hematopoietic stem cell transplantation
- cell cycle arrest
- signaling pathway
- magnetic resonance
- case report
- gene expression
- quality improvement
- transcription factor
- squamous cell carcinoma
- magnetic resonance imaging
- copy number
- stem cells
- metastatic colorectal cancer
- cell death
- computed tomography
- oxidative stress
- radiation therapy
- dna methylation
- mesenchymal stem cells
- replacement therapy